Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.42
WAT's Cash to Debt is ranked higher than
50% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.42 vs. WAT: 1.42 )
Ranked among companies with meaningful Cash to Debt only.
WAT' s 10-Year Cash to Debt Range
Min: 0  Med: 0.98 Max: 336.71
Current: 1.42
0
336.71
Equity to Asset 0.48
WAT's Equity to Asset is ranked lower than
69% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. WAT: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
WAT' s 10-Year Equity to Asset Range
Min: -0.04  Med: 0.44 Max: 0.7
Current: 0.48
-0.04
0.7
Interest Coverage 15.15
WAT's Interest Coverage is ranked lower than
66% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.79 vs. WAT: 15.15 )
Ranked among companies with meaningful Interest Coverage only.
WAT' s 10-Year Interest Coverage Range
Min: 1.86  Med: 17.72 Max: 9999.99
Current: 15.15
1.86
9999.99
F-Score: 7
Z-Score: 6.57
M-Score: -2.67
WACC vs ROIC
2.71%
37.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 27.19
WAT's Operating margin (%) is ranked higher than
93% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.07 vs. WAT: 27.19 )
Ranked among companies with meaningful Operating margin (%) only.
WAT' s 10-Year Operating margin (%) Range
Min: 8.08  Med: 24.60 Max: 28.55
Current: 27.19
8.08
28.55
Net-margin (%) 22.65
WAT's Net-margin (%) is ranked higher than
93% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.95 vs. WAT: 22.65 )
Ranked among companies with meaningful Net-margin (%) only.
WAT' s 10-Year Net-margin (%) Range
Min: -1.78  Med: 18.02 Max: 25.03
Current: 22.65
-1.78
25.03
ROE (%) 24.69
WAT's ROE (%) is ranked higher than
93% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.63 vs. WAT: 24.69 )
Ranked among companies with meaningful ROE (%) only.
WAT' s 10-Year ROE (%) Range
Min: -12.26  Med: 37.73 Max: 68.79
Current: 24.69
-12.26
68.79
ROA (%) 12.11
WAT's ROA (%) is ranked higher than
85% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.88 vs. WAT: 12.11 )
Ranked among companies with meaningful ROA (%) only.
WAT' s 10-Year ROA (%) Range
Min: -1.81  Med: 15.53 Max: 22.73
Current: 12.11
-1.81
22.73
ROC (Joel Greenblatt) (%) 75.82
WAT's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. WAT: 75.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
WAT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 15.56  Med: 94.67 Max: 137.37
Current: 75.82
15.56
137.37
Revenue Growth (3Y)(%) 5.20
WAT's Revenue Growth (3Y)(%) is ranked higher than
52% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. WAT: 5.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
WAT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 5.2  Med: 10.20 Max: 19.5
Current: 5.2
5.2
19.5
EBITDA Growth (3Y)(%) 4.00
WAT's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. WAT: 4.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
WAT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 2.4  Med: 11.80 Max: 69.7
Current: 4
2.4
69.7
EPS Growth (3Y)(%) 2.60
WAT's EPS Growth (3Y)(%) is ranked lower than
56% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. WAT: 2.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
WAT' s 10-Year EPS Growth (3Y)(%) Range
Min: 2.6  Med: 15.75 Max: 79.2
Current: 2.6
2.6
79.2
» WAT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

WAT Guru Trades in Q2 2014

Jeremy Grantham 176,039 sh (+30.97%)
Paul Tudor Jones 4,400 sh (+2.33%)
Chuck Royce 13,250 sh (unchged)
Pioneer Investments 21,592 sh (unchged)
John Hussman Sold Out
Ruane Cunniff 2,066,476 sh (-0.37%)
PRIMECAP Management 1,035,761 sh (-0.46%)
Jim Simons 18,800 sh (-84.46%)
» More
Q3 2014

WAT Guru Trades in Q3 2014

Joel Greenblatt 137,466 sh (New)
Ray Dalio 3,600 sh (New)
Jim Simons 289,500 sh (+1439.89%)
Paul Tudor Jones 5,568 sh (+26.55%)
Chuck Royce 13,250 sh (unchged)
Pioneer Investments 21,592 sh (unchged)
Ruane Cunniff 2,050,578 sh (-0.77%)
Jeremy Grantham 174,539 sh (-0.85%)
PRIMECAP Management 983,434 sh (-5.05%)
» More
Q4 2014

WAT Guru Trades in Q4 2014

Jim Simons 494,700 sh (+70.88%)
Chuck Royce 13,250 sh (unchged)
Ray Dalio Sold Out
Ruane Cunniff 2,049,064 sh (-0.07%)
PRIMECAP Management 975,734 sh (-0.78%)
Jeremy Grantham 164,415 sh (-5.80%)
Pioneer Investments 16,512 sh (-23.53%)
Paul Tudor Jones 3,600 sh (-35.34%)
Joel Greenblatt 56,395 sh (-58.98%)
» More
Q1 2015

WAT Guru Trades in Q1 2015

John Hussman 27,000 sh (New)
Chuck Royce 15,450 sh (+16.60%)
Ruane Cunniff 2,049,264 sh (+0.01%)
Paul Tudor Jones Sold Out
PRIMECAP Management 973,611 sh (-0.22%)
Jim Simons 415,100 sh (-16.09%)
Jeremy Grantham 137,415 sh (-16.42%)
Joel Greenblatt 46,450 sh (-17.63%)
Pioneer Investments 2,825 sh (-82.89%)
» More
» Details

Insider Trades

Latest Guru Trades with WAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.92
WAT's P/E(ttm) is ranked higher than
66% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.10 vs. WAT: 23.92 )
Ranked among companies with meaningful P/E(ttm) only.
WAT' s 10-Year P/E(ttm) Range
Min: 9.62  Med: 20.64 Max: 32.19
Current: 23.92
9.62
32.19
Forward P/E 20.37
WAT's Forward P/E is ranked higher than
59% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.98 vs. WAT: 20.37 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.20
WAT's PE(NRI) is ranked higher than
63% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.00 vs. WAT: 24.20 )
Ranked among companies with meaningful PE(NRI) only.
WAT' s 10-Year PE(NRI) Range
Min: 9.61  Med: 20.65 Max: 32.25
Current: 24.2
9.61
32.25
P/B 5.79
WAT's P/B is ranked lower than
79% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. WAT: 5.79 )
Ranked among companies with meaningful P/B only.
WAT' s 10-Year P/B Range
Min: 4.38  Med: 6.86 Max: 20.15
Current: 5.79
4.38
20.15
P/S 5.42
WAT's P/S is ranked lower than
71% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. WAT: 5.42 )
Ranked among companies with meaningful P/S only.
WAT' s 10-Year P/S Range
Min: 2.05  Med: 4.35 Max: 5.72
Current: 5.42
2.05
5.72
PFCF 24.63
WAT's PFCF is ranked higher than
67% of the 81 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.24 vs. WAT: 24.63 )
Ranked among companies with meaningful PFCF only.
WAT' s 10-Year PFCF Range
Min: 9.67  Med: 20.78 Max: 32.21
Current: 24.63
9.67
32.21
POCF 19.86
WAT's POCF is ranked lower than
51% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.89 vs. WAT: 19.86 )
Ranked among companies with meaningful POCF only.
WAT' s 10-Year POCF Range
Min: 7.83  Med: 16.96 Max: 24.7
Current: 19.86
7.83
24.7
EV-to-EBIT 18.29
WAT's EV-to-EBIT is ranked higher than
62% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.04 vs. WAT: 18.29 )
Ranked among companies with meaningful EV-to-EBIT only.
WAT' s 10-Year EV-to-EBIT Range
Min: 8.4  Med: 16.50 Max: 25.2
Current: 18.29
8.4
25.2
PEG 2.78
WAT's PEG is ranked higher than
55% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.97 vs. WAT: 2.78 )
Ranked among companies with meaningful PEG only.
WAT' s 10-Year PEG Range
Min: 0.6  Med: 1.62 Max: 4.26
Current: 2.78
0.6
4.26
Shiller P/E 26.75
WAT's Shiller P/E is ranked higher than
60% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.41 vs. WAT: 26.75 )
Ranked among companies with meaningful Shiller P/E only.
WAT' s 10-Year Shiller P/E Range
Min: 13.46  Med: 25.32 Max: 44.59
Current: 26.75
13.46
44.59
Current Ratio 5.34
WAT's Current Ratio is ranked higher than
83% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.56 vs. WAT: 5.34 )
Ranked among companies with meaningful Current Ratio only.
WAT' s 10-Year Current Ratio Range
Min: 1.19  Med: 1.85 Max: 5.34
Current: 5.34
1.19
5.34
Quick Ratio 4.86
WAT's Quick Ratio is ranked higher than
86% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.68 vs. WAT: 4.86 )
Ranked among companies with meaningful Quick Ratio only.
WAT' s 10-Year Quick Ratio Range
Min: 0.74  Med: 1.38 Max: 4.86
Current: 4.86
0.74
4.86
Days Inventory 115.93
WAT's Days Inventory is ranked higher than
57% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 125.77 vs. WAT: 115.93 )
Ranked among companies with meaningful Days Inventory only.
WAT' s 10-Year Days Inventory Range
Min: 96.3  Med: 109.47 Max: 155.02
Current: 115.93
96.3
155.02
Days Sales Outstanding 71.29
WAT's Days Sales Outstanding is ranked lower than
64% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.15 vs. WAT: 71.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
WAT' s 10-Year Days Sales Outstanding Range
Min: 67.61  Med: 79.83 Max: 89.8
Current: 71.29
67.61
89.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 108.71
WAT's Price/Net Cash is ranked lower than
91% of the 44 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.26 vs. WAT: 108.71 )
Ranked among companies with meaningful Price/Net Cash only.
WAT' s 10-Year Price/Net Cash Range
Min: 104.47  Med: 225.27 Max: 401.52
Current: 108.71
104.47
401.52
Price/Net Current Asset Value 12.42
WAT's Price/Net Current Asset Value is ranked lower than
63% of the 108 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.96 vs. WAT: 12.42 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
WAT' s 10-Year Price/Net Current Asset Value Range
Min: 9.11  Med: 19.88 Max: 310.33
Current: 12.42
9.11
310.33
Price/Tangible Book 8.27
WAT's Price/Tangible Book is ranked lower than
74% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.32 vs. WAT: 8.27 )
Ranked among companies with meaningful Price/Tangible Book only.
WAT' s 10-Year Price/Tangible Book Range
Min: 6.42  Med: 13.49 Max: 1313.3
Current: 8.27
6.42
1313.3
Price/Projected FCF 1.75
WAT's Price/Projected FCF is ranked lower than
51% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.77 vs. WAT: 1.75 )
Ranked among companies with meaningful Price/Projected FCF only.
WAT' s 10-Year Price/Projected FCF Range
Min: 0.87  Med: 1.61 Max: 11.02
Current: 1.75
0.87
11.02
Price/DCF (Earnings Based) 1.34
WAT's Price/DCF (Earnings Based) is ranked higher than
72% of the 18 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.72 vs. WAT: 1.34 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.25
WAT's Price/Median PS Value is ranked lower than
52% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.24 vs. WAT: 1.25 )
Ranked among companies with meaningful Price/Median PS Value only.
WAT' s 10-Year Price/Median PS Value Range
Min: 0.14  Med: 0.97 Max: 3.56
Current: 1.25
0.14
3.56
Price/Peter Lynch Fair Value 3.29
WAT's Price/Peter Lynch Fair Value is ranked lower than
82% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.96 vs. WAT: 3.29 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
WAT' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.68  Med: 1.56 Max: 5.59
Current: 3.29
0.68
5.59
Price/Graham Number 2.94
WAT's Price/Graham Number is ranked lower than
59% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.51 vs. WAT: 2.94 )
Ranked among companies with meaningful Price/Graham Number only.
WAT' s 10-Year Price/Graham Number Range
Min: 2.3  Med: 3.51 Max: 20.36
Current: 2.94
2.3
20.36
Earnings Yield (Greenblatt) (%) 5.54
WAT's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. WAT: 5.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
WAT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 4  Med: 6.10 Max: 11.9
Current: 5.54
4
11.9
Forward Rate of Return (Yacktman) (%) 10.68
WAT's Forward Rate of Return (Yacktman) (%) is ranked lower than
51% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.68 vs. WAT: 10.68 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
WAT' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 8.9  Med: 15.80 Max: 27.6
Current: 10.68
8.9
27.6

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:WAZ.Germany,
Waters Corp incorporated as a Delaware corporation in 1991, is an analytical instrument manufacturer, mainly designs, manufactures, sells and services, through its Waters Division, high performance liquid chromatography, ultra performance liquid chromatography and mass spectrometry instrument systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. Waters became a publicly-traded company with its initial public offering ("IPO") in November 1995. The Company's two operating segments, Waters Division and TA Division, have similar economic characteristics; product processes; products and services; types and classes of customers; methods of distribution and regulatory environments. The Waters Division's products and services consist of high performance liquid chromatography ("HPLC"), ultra performance liquid chromatography ("UPLC" and together with HPLC, referred to as "LC"), mass spectrometry ("MS") and chemistry consumable products and related services. TA products and services consist of thermal analysis, rheometry and calorimetry instrument systems and service sales. The Company's products are used by pharmaceutical, life science, biochemical, industrial, nutritional safety, environmental, academic and governmental customers. These customers use the Company's products to detect, identify, monitor and measure the chemical, physical and biological composition of materials and to predict the suitability of fine chemicals, pharmaceuticals, water, polymers and viscous liquids in various industrial, consumer goods and healthcare products. The Company's competitors include: Agilent Technologies, Inc., Shimadzu Corporation, Bruker Corporation, Danaher Corporation and Thermo Fisher Scientific Inc. In the markets served by the TA Division, the Company's principal competitors include: PerkinElmer, Inc., Mettler-Toledo International Inc., NETZSCH-Geraetebau GmbH, Thermo Fisher Scientific Inc., Malvern Instruments Ltd., Anton-Paar and General Electric Company.
» More Articles for WAT

Headlines

Articles On GuruFocus.com
Study May 29 2015 
Weekly Insider Sells Highlight: WAT, KO, GILD, AZO, MAS Dec 14 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
Our Investment Strategy and Portfolio Selection Nov 09 2014 
Guru-Held Stocks Trading At Historical Low P/B Oct 08 2014 
Guru Held Stocks Near Historical Low P/B Jul 22 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Jun 02 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 27 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 19 2014 
Morning Coffee: Widely Held Guru Stocks Near Historic Low P/B May 12 2014 

More From Other Websites
Waters Corporation Announces Christopher J. O'Connell as Chief Executive Officer Jun 25 2015
WATERS CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Jun 25 2015
Waters Corporation Announces Christopher J. O'Connell as Chief Executive Officer Jun 25 2015
Why Agilent Technologies is a "Hold" Jun 17 2015
Waters Introduces the New ACQUITY Arc System, Designed as a Bridge between HPLC and UPLC Methods Jun 14 2015
Waters New Release of UNIFI Scientific Information System Software Offers New MS Instrument Support... Jun 14 2015
Waters New Vion IMS Q-Tof Mass Spectrometer Brings the Benefits of Ion Mobility and Greater... Jun 14 2015
Waters new REIMS Research System with iKnife Technology Reduces Sampling Time to Seconds Jun 14 2015
Waters New HILIC-based Glycoprotein Column Enhances Glycan Analysis Jun 14 2015
Waters Brings Novel Separations and Ionization Technologies to High Resolution Mass Spectrometry at... Jun 14 2015
Waters Oasis PRiME HLB Sample Extraction Family Sets New Standard for LC and LC-MS Sample... Jun 14 2015
Agilent Technologies and Waters Corporation Formalize Instrument Control Exchange Jun 11 2015
Waters Welcomes Chang Gung University as Taiwan’s First Centers of Innovation Program Partner Jun 11 2015
Waters Welcomes Chang Gung University as Taiwan’s First Centers of Innovation Program Partner Jun 11 2015
Agilent Technologies and Waters Corporation Formalize Instrument Control Exchange Jun 11 2015
Edited Transcript of WAT presentation 10-Jun-15 4:20pm GMT Jun 11 2015
Waters Corporation Presentation at the Goldman Sachs 36th Annual Global Healthcare Conference to Be... Jun 04 2015
Waters Launches 5 Novel Mass Spectrometry Technologies - Analyst Blog May 28 2015
Waters Brings Novel Separations and Ionization Technologies to High Resolution Mass Spectrometry at... May 27 2015
Waters Brings Novel Separations and Ionization Technologies to High Resolution Mass Spectrometry at... May 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK